From the Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at the University of California (Bonnet, Miller), Los Angeles, California, USA; Opthalmôle de Paris, Cochin Hospital, Paris Descartes University (Bonnet), Paris, France.
J Cataract Refract Surg. 2020 Jun;46(6):893-901. doi: 10.1097/j.jcrs.0000000000000172.
To assess the preliminary safety and efficacy of custom silicone artificial iris implantation.
Stein Eye Institute.
Prospective consecutive case series.
Medical records of patients implanted with the artificial iris were reviewed and followed for 1 year. Safety measures included corrected distance visual acuity (CDVA), intraocular pressure (IOP), endothelial cell count (ECC), surgical complications, secondary interventions, and adverse events (AEs). Efficacy measures included CDVA with glare, subjective daytime and nighttime glare graded from 0 to 10 (very significant), and subjective cosmetic appearance graded from 0 to 10 (very satisfied).
Twenty eyes (19 patients) were implanted. Safety data were mixed. CDVA improved in 13 eyes and worsened in 6. ECC decreased from 1918 ± 870 to 1405 ± 705 cells/mm (P = .02). Eight eyes experienced postoperative complications. There were 4 IOP elevations, 2 corneal decompensations, 1 case of cystoid macular edema, and 1 device dislocation. Four eyes underwent secondary surgical interventions including 2 AEs (1 glaucoma surgery and 1 device dislocation). Efficacy outcomes were excellent. CDVA with glare improved from 1.5 ± 0.6 to 0.7 ± 0.8 logarithm of the minimum angle of resolution (P < .01). Mean subjective daytime glare decreased from 8.9 ± 1.8 to 2.7 ± 2.6 (P < .01) and nighttime glare decreased from 7.9 ± 1.8 to 2.5 ± 2.7 (P < .01). Mean cosmesis improved from 2.2 ± 1.6 to 8.8 ± 2.1 (P < .01).
Custom artificial iris implantation was moderately risky but very effective at reducing light and glare sensitivity and in improving ocular cosmesis.
评估定制硅胶人工虹膜植入的初步安全性和有效性。
Stein 眼科研究所。
前瞻性连续病例系列。
回顾接受人工虹膜植入的患者的病历,并进行了为期 1 年的随访。安全性评估指标包括矫正远距视力(CDVA)、眼内压(IOP)、内皮细胞计数(ECC)、手术并发症、二次干预和不良事件(AE)。有效性评估指标包括眩光时的 CDVA、白天和夜间眩光的主观评分(从 0 到 10 分,非常显著)和主观美容外观评分(从 0 到 10 分,非常满意)。
共植入 20 只眼(19 名患者)。安全性数据参差不齐。13 只眼的 CDVA 提高,6 只眼的 CDVA 下降。ECC 从 1918±870 个细胞/mm²降至 1405±705 个细胞/mm²(P=.02)。8 只眼发生术后并发症。有 4 只眼眼压升高,2 只眼角膜失代偿,1 只眼发生黄斑囊样水肿,1 只眼发生设备脱位。4 只眼进行了二次手术干预,包括 2 例 AE(1 例青光眼手术和 1 例设备脱位)。有效性结果极佳。眩光时的 CDVA 从 1.5±0.6 提高到 0.7±0.8 最小分辨角对数(logMAR)(P<.01)。白天的平均主观眩光从 8.9±1.8 降低至 2.7±2.6(P<.01),夜间的平均主观眩光从 7.9±1.8 降低至 2.5±2.7(P<.01)。美容外观的平均评分从 2.2±1.6 提高到 8.8±2.1(P<.01)。
定制人工虹膜植入术风险中等,但能有效降低光和眩光敏感度,改善眼部美容效果。